NB 1001

Drug Profile

NB 1001

Alternative Names: GLP-1-XTEN; NB1001; XTEN™-GLP-1

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amunix
  • Developer Naia Limited
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Short bowel syndrome
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Short-bowel-syndrome in USA
  • 15 Nov 2017 United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA) approves clinical trial authorisation (CTA) for clinical trial in Short bowel syndrome
  • 06 Apr 2017 Naia Rare Diseases intends to launch NB 1001 for Short bowel syndrome in 2019 (Naia Rare Diseases website, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top